Tirzepatide ���子背景与靶点 — Explained

By Editorial Desk · published 2025-08-26 · last reviewed 2025-09-24 · News

If you have been reading about incretin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-09-24. Where a claim depends on a specific study, the study is described rather than over-claimed.

Tirzepatide 分子背景与靶点

该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。

当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。

Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。

Background And Receptor Pharmacology

Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.

Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.

Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.

Tirzepatide at a glance

Analytical Methods, Stability and Verification

Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.

Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.

Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.

Related pages on this site

• Focused workbook
• Material summary
• Optimized checklist
• Focused overview
• Clear guide
• Efficient briefing
• Comprehensive overview
• Robust digest

Analytical Characterisation and Storage Practice

Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.

Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.

Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.

Tirzepatide Pharmacology and Development History

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.

Background and Dual Receptor Pharmacology

Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.

Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.

Supporting material

=== Laminin === Laminins are proteins found in the basal laminae of virtually all animals. Rather than forming collagen-like fibers, laminins form networks of web-like structures that resist tensile forces in the basal lamina. They also assist in cell adhesion. Laminins bind other ECM components such as collagens and nidogens.

Rheumatoid arthritis - autoimmune disease with an unclear cause that manifests as symmetric, erosive synovitis and, occasionally, extraarticular involvement. Systemic lupus erythematosus - chronic, complex autoimmune inflammatory disorder that can affect every organ in the body. Scleroderma and systemic scleroderma - diverse collection of autoimmune fibrosing conditions. Dermatomyositis and polymyositis - autoimmune myopathies that are clinically characterized by extramuscular symptoms, muscle inflammation, proximal muscle weakening, and oftentimes the detection of autoantibodies. Antisynthetase syndrome - multisystematic autoimmune disease associated with inflammatory myositis and interstitial lung disease. Vasculitis - disease that results in blood vessel inflammation. Sjögren's disease - a systemic autoimmune illness that mostly affects the exocrine glands and causes mucosal surfaces, especially those in the mouth and eyes, to become extremely dry. Rheumatic fever - multisystem inflammatory illness that develops after group A streptococcal pharyngitis. Amyloidosis - uncommon condition caused by protein mutations or changes in the body that result in twisted clusters of malformed proteins accumulating on organs and tissues. Osteoarthritis - common articular cartilage degenerative disease linked to hypertrophic bone abnormalities.

A major factor is mechanical deformation of the extracellular matrix, which can affect the actin cytoskeleton and therefore affect cell shape, motility, and function. Mechanical forces can be transmitted by focal adhesion sites, integrins, and cell-cell junctions. Changes in the actin cytoskeleton can activate integrins, which mediate "outside-in" and "inside-out" signaling between the cell and the matrix. G-proteins, which induce intracellular signaling cascades, may also be important, and ion channels are activated by stretching to allow ions such as calcium, sodium, or potassium to enter the cell.

60–85% collagen 60–80% collagen I 0–10% collagen III 2% collagen IV small amounts of collagens V, VI, and others 15–40% non-collagenous extracellular matrix components, including: 3% cartilage oligomeric matrix protein, 1–2% elastin, 1–5% proteoglycans, 0.2% inorganic components such as copper, manganese, and calcium. Although most of a tendon's collagen is type I collagen, many minor collagens are present that play vital roles in tendon development and function. These include type II collagen in the cartilaginous zones, type III collagen in the reticulin fibres of the vascular walls, type IX collagen, type IV collagen in the basement membranes of the capillaries, type V collagen in the vascular walls, and type X collagen in the mineralized fibrocartilage near the interface with the bone.

== Biological aspects == Americium is an artificial element of recent origin, and thus does not have a biological requirement. It is harmful to life. It has been proposed to use bacteria for removal of americium and other heavy metals from rivers and streams. Thus, Enterobacteriaceae of the genus Citrobacter precipitate americium ions from aqueous solutions, binding them into a metal-phosphate complex at their cell walls. Several studies have been reported on the biosorption and bioaccumulation of americium by bacteria and fungi. In the laboratory, both americium and curium were found to support the growth of methylotrophs.

Sources: en.wikipedia.org

Supporting material

Glimepiride is an antidiabetic medication within the sulfonylurea class, primarily prescribed for the management of type 2 diabetes. It is regarded as a second-line option compared to metformin, due to metformin's well-established safety and efficacy. Use of glimepiride is recommended in conjunction with lifestyle modifications such as diet and exercise. It is taken by mouth, reaching a peak effect within three hours and lasting for about a day. Common side effects include headache, nausea, and dizziness. Serious side effects may include low blood sugar. Use during pregnancy and breastfeeding is not recommended. It works predominantly by increasing the amount of insulin released from the pancreas. It is classified as a second-generation sulfonylurea. Glimepiride was patented in 1979 and approved for medical use in 1995. It is available as a generic medication. In 2023, it was the 80th most commonly prescribed medication in the United States, with more than 8 million prescriptions.

=== Organized crime allegations === Thaçi was alleged of having extensive criminal links. During his time as head of the Kosovo Liberation Army, The Washington Times reported that the KLA was financing its activities by trafficking heroin and cocaine into western Europe. The KLA received an estimated $75–100 million from the Albanian diaspora in Europe and the United States. There is a possibility that among donors to the KLA were people involved in illegal activities such as drug trafficking; however, insufficient evidence exists to prove direct KLA involvement. The BBC reported in 2000 that Thaçi was allegedly central to the criminal activities of the Kosovo Protection Corps (KPC), who reportedly extorted money from businessmen under the guise of "taxes" for his self-appointed government. While the KLA was officially disbanded at the end of armed conflict in Kosovo in 1999, the new Kosovo Protection Corps was composed primarily of former KLA fighters and the Democratic Party of Kosovo (PDK). The party was formed largely from the political leadership of the KLA. A near monopoly on the means of force, based on the absorption of the KLA into the KPC, allowed the Democratic Party of Kosovo to seize control of the machinery of government at the municipal level. The PDK regularly used violence and intimidation of political rivals to maintain local political control and protect criminal enterprises that depend upon cooperation from friendly local authorities. In 2001, the Democratic Party of Kosovo suffered electoral defeat in the first free elections in the province in 2001.

Jerry Gallwas (born 1936) is an American rock climber active in the 1950s during the dawn of the Golden Age of Yosemite Rock Climbing. He achieved a number of pioneering first ascents including sandstone spires in the American Southwest, and the first ascent of the Northwest Face of Half Dome with Royal Robbins and Mike Sherrick in 1957. Gallwas made his own heat-treated chrome-molybdenum steel alloy pitons, which contributed to the success of the climb. Gallwas studied chemistry at San Diego State University and spent much of his career working for scientific instrument maker Beckman Instruments, Inc. He helped to develop consensus standards for laboratory medicine, and served on the board of directors and as president of the National Committee for Clinical Laboratory Standards.

=== DMPK, ADME, and bioanalysis === BioDuro conducts in vitro ADME assays, in vivo PK/TK studies, metabolic stability studies, and bioanalytical method development using LC–MS/MS platforms. These services are used to characterize compound absorption, distribution, metabolism, and excretion profiles during preclinical development.

== Recognition == From 1953 to 1962, Gross served on the Committee on the Skeletal System for the National Research Council. During that period, from 1956 to 1960, he was appointed Associate Editor of the Journal of Histochemistry and Cytochemistry. In 1956, he was named an Established Investigator for the American Heart Association. Gross's most longstanding post was at the Helen Hay Whitney Foundation at the Scientific Advisory Committee, where he served from 1956 to 1991. In 1959, he received the Ciba Foundation Award for Research Relevant to the Problems of Aging. That same year he was appointed to the Advisory Panel on Molecular Biology at the National Science Foundation, where he served until 1962. That year he served as chairman of the Board of Scientific Counselors at the National Institute of Dental Research. He remained in that position until 1966. In 1963, Gross won the Special Award of the Society of Cosmetic Chemists. That same year he was named Advisory Editor for the Journal of Cosmetic Chemists, where he remained until 1971. From 1965 to 1968 he was Consulting Editor at Developmental Biology. In 1966, he was elected to fellowship in the American Academy of Arts and Sciences. Eight years later he was elected to membership in the National Academy of Sciences. Gross served on the editorial board of the Journal of Biological Chemistry from 1976 to 1981 and Chairman of the Committee on Research, MGH, from 1979 to 1982. He joined the Board of Trustees of the Helen Hay Whitney Foundation in 1985.

Sources: en.wikipedia.org

Notes from published material

These ideas received wide and influential backing, when James Cook set off to circumnavigate the world (1768–1771) in HM Bark Endeavour, malt and wort were top of the list of the remedies he was ordered to investigate. The others were beer, sauerkraut (a good source of vitamin C), and Lind's 'rob'. The list did not include lemons. Cook did not lose a single man to scurvy, and his report came down in favor of malt and wort. The reason for the health of his crews on this and other voyages was Cook's regime of shipboard cleanliness, enforced by strict discipline, and frequent replenishment of fresh food and greenstuffs. Another beneficial rule implemented by Cook was his prohibition of the consumption of salt fat skimmed from the ship's copper boiling pans, then a common practice elsewhere in the Navy. In contact with air, the copper formed compounds that prevented the absorption of vitamins by the intestines. The first major long-distance expedition that experienced virtually no scurvy was that of the Spanish naval officer Alessandro Malaspina, 1789–1794. Malaspina's medical officer, Pedro González, was convinced that fresh oranges and lemons were essential for preventing scurvy. Only one outbreak occurred, during a 56-day trip across the open sea. Five sailors came down with symptoms, one seriously. After three days at Guam, all five were healthy again. Spain's large empire and many ports of call made it easier to acquire fresh fruit.

244Cm(12C,xn)256−xNo (x=4,5) This reaction was studied in 1958 by scientists at the LBNL using a 95% 244Cm curium target. They were able to measure 7.43 MeV decays from250Fm, associated with a 3 s 254No parent activity, resulting from the reaction (246Cm,4n). The 3 s activity was later reassigned to252No, resulting from reaction (244Cm,4n). It could however not be proved that it was not due to the contaminant 250mFm, unknown at the time. Later work in 1959 produced 8.3 MeV alpha particles with a half-life of 3 s and a 30% SF branch. This was initially assigned to 254No and later reassigned to 252No, resulting from reaction with the 244Cm component in the target. The reaction was restudied in 1967 at the LBNL and a new activity assigned to 251No was measured.

Its use is generally restricted to severe infections largely in hospitalized patients. The recommended dosage is 250 mg to 1 gram given intravenously every 6 to 8 hours or in intramuscular doses of no more than 1.5 gm daily, usually for five to 14 days. It is commercially available as Primaxin as 250-mg or 500-mg infusion bottles for IV use or 500-mg or 750-mg vials of lyophilized powder for IM injection. The most common side effects of imipenem are diarrhea, nausea, vomiting, skin rash, pruritus, and injection-site reactions.

=== Sources === Peng, Dixian; Shu, Guofan (1990). 刘文辉史话 [Historical Tales of Liu Wenhui] (in Chinese). Chengdu: Sichuan University Press. ISBN 7-5614-0298-8. Lawson, Joe (2011). Xikang: Han Chinese in Sichuan's Western Frontier, 1905-1949 (PhD thesis). University of Wellington. doi:10.26686/wgtn.17011421. Kim, Hee-shin (2007). "남경국민정부시기 劉文輝와 川康 政治" [Liu Wenhui and the Politics of Sichuan and Xikang during the Nationalist Government Period]. 中國學報. 56: 311–341 – via Korea Citation Index. Leibold, James (2007). Reconfiguring Chinese Nationalism: How the Qing Frontier and its Indigenes Became Chinese. Basingstoke: Palgrave Macmillan. ISBN 978-1-4039-7479-2.

Sources: en.wikipedia.org

Frequently asked questions